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Abstract
Background: In some hypertensive patients, psychological stress makes blood pressure difficult
to control and causes physical symptoms such as headache or dizziness. We report the case of a
hypertensive man whose psychological stress-induced increase in blood pressure was attenuated
by cilnidipine.
Case Presentation: The patient (a 72-year-old man) had hypertension and was on
antihypertensive therapy. When mentally concentrating, he experienced occipital headaches and
dizziness, and despite thorough testing, no abnormality was found. He was subsequently referred
to our department. The mirror drawing test (MDT), a psychological stress test, increased blood
pressure by about 40 mmHg, and the patient described occipital headache. Plasma noradrenaline
level also increased from 212 to 548 pg/ml. We therefore switched the patient from nifedipine, an
L-type calcium (Ca) channel blocker, to cilnidipine, an L-type/N-type Ca channel blocker with
suppressive effects on sympathetic activity. Cilnipidine attenuated MDT-induced an increase in
blood pressure and plasma noradrenaline level and prevented the development of headache during
testing.
Conclusion:  These findings suggest that cilnidipine is a useful antihypertensive agent for
hypertensive patients in whom psychological stress causes marked fluctuations in blood pressure.
Background
In hypertensive patients (especially men), the sympa-
thetic nervous system is overreactive and stress-induced
increases in blood pressure are greater in hypertensive
than healthy subjects [1-3]. Therefore, in some hyperten-
sive patients, psychological stress makes blood pressure
difficult to control, decreasing quality of life (QOL). Fur-
thermore, psychological stress-induced increase in blood
pressure has been demonstrated to be an independent
contributor to left ventricular hypertrophy in hypertensive
men [3,4]. Therefore, control of psychological stress-
induced, exaggerated increase in blood pressure is impor-
tant from the viewpoint of preventing left ventricular
hypertrophy as well as improving QOL in hypertensive
men.
Cilnidipine (Atelec; Mochida Pharmaceutical, Tokyo,
Japan) is a dihydropyridine calcium (Ca) antagonist,
which like conventional Ca antagonists exhibits antihy-
pertensive activities via L-type Ca channel inhibition, but
it also suppresses the sympathetic nervous system via N-
type voltage-dependent Ca channels [5]. Thus, cilnidipine
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was demonstrated to suppress stress-induced hyperten-
sion in rats [6]. We, therefore, expected that cilnidipine
would benefit hypertensive patients with impaired QOL
in whom psychological stress alters blood pressure.
We present herein the case of a hypertensive man success-
fully treated for psychological stress-induced, marked
blood pressure increases and occipital headaches that hin-
dered his activities of daily living. The efficacy of ciln-
idipine was demonstrated using the mirror drawing test
(MDT).
Case Presentation
Patient
A 74-year-old man.
Chief complaint
Occipital headache when concentrating.
Family history
No family history of hypertension.
Medical history
Nothing of note.
Life history
No history of smoking. About 350 ml/day of beer.
History of present illness
The patient was diagnosed with hypertension at about 40
years of age, and he has since been taking slow-release
nifedipine tablets. Blood pressure was controlled at about
130/80 mmHg, but in April 200X, he began to experience
non-pulsatile occipital headaches and dizziness when
concentrating on work or whenever mental focus was
required. These conditions were severe enough to impair
activities of daily living. For example, on several occasions
he had to excuse himself from meetings. Occipital head-
aches had no relation to nifedipine administration. Also,
when the patient experienced occipital headaches, systolic
blood pressure was about 50 mmHg higher than usual.
His family physician ordered blood tests and head mag-
netic resonance imaging (MRI), but no abnormalities
were found. Since the involvement of psychological stress
was suspected, the patient was referred to our department
at the end of May and was admitted for thorough testing
on June 5.
Physical findings
Height 161.6 cm, body weight 59.7 kg, body temperature
36.5°C, blood pressure 120/64 mmHg, heart rate (HR) 60
beats/min and regular. No yellowing of the bulbar con-
junctiva. No anemia using palpebral conjunctiva hue. No
abnormalities in the chest, heart, or respiratory sounds.
No abdominal abnormality. No leg edema. No neurolog-
ical abnormality. Marked bilateral palmar sweating.
Psychosocial background
The patient was very detail-oriented and a perfectionist.
For several years, he had served as a board member of a
company as well as a few community and elderly groups.
In April, he was particularly busy and under great stress
due to personal relationship issues involving some group
members.
Test findings on admission
No abnormal blood count findings. Blood biochemical
analysis showed no abnormalities, including total choles-
terol (205 mg/dl) and triglycerides (128 mg/dl). Endo-
crinological testing conducted at rest in the early morning
showed no abnormalities: plasma rennin activity, 1.8 ng/
ml/hr; aldosterone, 81.0 pg/ml; adrenaline, 27 pg/ml; and
noradrenaline (NA) 162 pg/ml. There was no cardiac dil-
atation (by chest radiography), no adrenal abnormalities
(by abdominal ultrasonography [US]), no signs of carotid
artery constriction (by US), no abnormality in the skull
(by head MRI), and no stenosis (by MRA). The head-up
tilt test did not confirm orthostatic hypotension.
Post-admission course (Fig. 1)
Even after admission, the patient experienced non-pulsa-
tile pain accompanied by heaviness in the back of the
head whenever thinking or frustrated. Before admission,
the patient was taking four antihypertensive agents (val-
sartan [80 mg], slow-release nifedipine [40 mg], temoc-
april [2 mg], and trichloromethiazide [2 mg]), but after
admission, use of trichloromethiazide and temocapril
was discontinued in that order. To investigate the effects
of psychological stress on the patient, the first MDT was
performed to measure changes in blood pressure, HR, and
plasma NA (the MDT protocol is described below). At 2
min after starting MDT, systolic blood pressure (SBP) and
diastolic blood pressure (DBP) increased by up to 38 and
36 mmHg, respectively, before gradually decreasing. In
addition, occipital headache was experienced at 2 min
after the start of MDT and persisted for 15 min (Fig. 2). On
June 21, use of slow-release nifedipine was discontinued
and 10 mg of cilnidipine was started. At 1 week after the
start of cilnidipine therapy, a second MDT was performed,
and the maximum increase in SBP was limited to 27
mmHg. The patient did not experience further bouts of
occipital headache. Cilnidipine dosage was increased to
20 mg, and a third MDT showed that the maximum
increase in SBP was 21 mmHg. Furthermore, maximum
increase in HR during MDT while the patient was on
nifedipine therapy was 48 beats/min, and this increase
was also suppressed by cilnidipine (at both 10- and 20-mg
doses).BioPsychoSocial Medicine 2007, 1:16 http://www.bpsmedicine.com/content/1/1/16
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To investigate the effects of psychological stress on sympa-
thetic nerve activities, the level of plasma NA was meas-
ured before and immediately after MDT (Fig. 3). Plasma
NA increased immediately after MDT by 336 pg/ml while
the patient was on nifedipine therapy, but the increase
was smaller when the patient was on 10 or 20 mg of ciln-
idipine (139 and 90 pg/ml, respectively). Cilnidipine thus
suppressed blood pressure, HR, and sympathetic activity
during the MDT.
However, several days after increasing the cilnidipine dos-
age to 20 mg, the patient experienced a different type of
dizziness when standing up to go to the bathroom.
Another head-up tilt test was conducted, and at 1 min
after standing up, the patient had a 24 mmHg decrease in
SBP. As cilnidipine was considered to have suppressed the
sympathetic activation associated with standing, the ciln-
idipine dosage was reduced to 10 mg. A subsequent head-
up tilt test revealed no orthostatic hypotension, and the
patient no longer experienced dizziness on standing.
While in the hospital, the patient's stress coping skills
were evaluated. Although excessive workload was thought
to be the cause of his psychological stress, the patient
could not abruptly resign from his various posts. He was
thus instructed to lighten his workload as much as possi-
ble and was discharged on July 11. Since then, he has been
free of occipital headaches, and his clinical course has
been favorable.
MDT
At 1 h before start of the test, a line was placed in the right
forearm to collect venous blood samples. After resting for
≥ 30 min, the MDT was performed for 10 min. After the
end of the MDT, the patient was asked to rest for 10 min.
During this time, blood pressure and HR were measured
every min. Plasma NA level was measured immediately
before and immediately after MDT. MDT was performed
three times during hospitalization, and all three tests were
administered at about 11:00 A.M. by the same investiga-
tor. To avoid habituation to the test, the patient was
instructed to start drawing from different positions in dif-
ferent directions and each test was conducted at least
seven days apart. Self-reported introspection was recorded
following each test and these introspections showed that
the degree of frustration experienced during the MDT was
comparable each time. Furthermore, during all three tests,
the patient was medicated with valsartan. Nifedipine (40
mg) had been discontinued after the first MDT (after
Post-admission clinical course Figure 1
Post-admission clinical course. Doses indicate daily doses. Resting blood pressure was measured while the patient was in a 
recumbent position at 07:00. MDT: mirror drawing test. MDT1: First MDT on June 20; MDT2: second MDT on June 28; 
MDT3: third MDT on July 7; SBP: systolic blood pressure; DBP: diastolic blood pressure.
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breakfast). Cilnidipine administration (10 mg, after
breakfast) was initiated on June 21, and the second MDT
was performed on June 28. Starting on July 1, cilnidipine
dosage was increased to 20 mg (after breakfast), and the
third MDT was performed on July 7.
Discussion
The present study demonstrated that cilnidipine sup-
pressed the MDT-induced increase in blood pressure,
tachycardia, and NA in a dose-dependent manner in a
hypertensive man.
The sympathetic nervous system of hypertensive animals
is overreactive to psychological stress. For example, when
subjecting rats to emotional stress (shaking), sympathetic
activity and blood pressure increased, but the degree of
increase was greater for spontaneous hypertensive rats
compared to normotensive rats [7]. Unlike nifedipine,
which has no effect on stress-induced hypertension and
tachycardia, cilnidipine suppresses these events [6].
Human studies have shown that cilnidipine is more effec-
tive than nifedipine or amlodipine and significantly atten-
uates the white coat phenomenon in hypertensive
patients [2], increase in catecholamine levels on the cold
pressor test [5], and workday hypertension [8]. The results
of the MDT in the present case are well in agreement with
these findings.
While our patient was on nifedipine, his SBP, DBP, and
HR during MDT increased 38 mmHg, 36 mmHg, and 48
beats/min, respectively. By comparison, mean increases in
SBP, DBP, and PR for 10 normotensive subjects at our
facility were 12.7 mmHg, 10.5 mmHg, and 7.7 beats/min,
respectively. Thus, the sympathetic nervous system of the
present patient clearly overreacted to psychological stress.
As with conventional Ca antagonists, cilnidipine blocks
the Ca++ influx from L-type Ca channels to suppress vaso-
constriction, and at the same time suppresses excessive
release of NA from sympathetic nerve endings by hinder-
ing Ca++ current via N-type Ca channels. The latter may
account for the inhibitory effect of cilnidipine on stress-
induced sympathetic hyperactivity in the present patient.
Furthermore, cilnidipine relieved headaches experienced
during the MDT or activities of daily living in this patient.
Among hypertensive patients, QOL may be impaired by
physical symptoms accompanying hypertension, such as
headache and dizziness. Cilnidipine may thus also make
hypertensive patients less vulnerable to stress-induced
physical complaints. As psychological stress-induced
increase in blood pressure has been demonstrated to cor-
relate positively with the left ventricular hypertrophy in
hypertensive men [3,4], the inhibitory effect of cilnidipine
Changes in plasma noradrenaline levels before and after the  MDT Figure 3
Changes in plasma noradrenaline levels before and after the 
MDT. Open square: Before MDT. Closed square: Immedi-
ately after MDT.
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on the stress-induced increase in blood pressure may also
slow the progress of, or prevent, left ventricular hypertro-
phy in hypertensive patients.
However, when cilnidipine dosage was increased to 20
mg, the patient experienced an orthostatic blood pressure
decrease. High-dose cilnidipine may suppress not only
psychological stress-induced sympathetic hyperactivity,
but also sympathetic reflexes occurring on standing. Cau-
tion must be exercised when administering high-dose cil-
nidipine.
There are several limitations in this study. Firstly, one crit-
icism might be that the results of the 2nd and the 3rd MDT
are due to the habituation effect. As was described in the
MDT section, we tried to avoid habituation to the test and
the patient reported that the degree of frustration felt after
each MDT was the same. Therefore, although the habitua-
tion effect cannot be totally excluded, it can be mini-
mized. Secondly, it is possible that the following factors
accompanying hospitalization affect the results, i.e., die-
tary changes especially Na intake, relief from daily stress,
or reduced anxiety. As the patient was not overweight and
his blood cholesterol level was within the normal range,
he was served only a low Na diet during hospitalization.
However, as the patient was well educated about Na
intake, his intake of Na was the same before and after
admission. The patient complained of headache even
after hospitalization, for example, during his interview.
These symptoms decreased after starting cilnidipine and
the patient did not experience headache after discharge.
Therefore, the involvement of these factors may also be
minimum. A placebo effect may be excluded because the
patient had an orthostatic decrease in blood pressure at
the higher dose of cilnidipine, which could only be due to
the pharmacologic effect of cilnidipine.
Conclusion
These results suggest that cilnidipine is a useful antihyper-
tensive agent in hypertensive patients experiencing
marked increases in blood pressure following psychologi-
cal stress. Cilnidipine may also improve stress-induced
physical symptoms in hypertensive patients. However,
further study is necessary to generalize the conclusions
drawn from this case report.
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